Precigen projects record Q1 revenue following permanent J-Code for PAPZIMEOS
Precigen (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of gene and cell therapies, has announced a significant acceleration in the commercial rollout of PAPZIMEOS™ (zopapogene imadenovec-drba), projecting first-quarter 2026 revenue to exceed $18 million.










